Media coverage about Puma Biotechnology (NYSE:PBYI) has trended somewhat positive on Monday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Puma Biotechnology earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 44.7953275192254 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern’s scoring:
Puma Biotechnology (PBYI) opened at 124.35 on Monday. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $127.02. The company’s 50-day moving average is $108.65 and its 200-day moving average is $77.41. The stock’s market capitalization is $4.63 billion.
Puma Biotechnology (NYSE:PBYI) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.78). Equities analysts anticipate that Puma Biotechnology will post ($8.69) earnings per share for the current year.
PBYI has been the topic of several analyst reports. Bank of America Corporation reissued a “buy” rating and issued a $117.00 target price (up from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. J P Morgan Chase & Co reissued a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Citigroup Inc. reissued a “buy” rating and issued a $114.00 target price on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reissued a “buy” rating and issued a $118.00 target price (up from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Finally, BidaskClub downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $124.89.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Puma Biotechnology (PBYI) Share Price” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/16/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-puma-biotechnology-pbyi-share-price.html.
In other news, SVP Richard Paul Bryce sold 1,998 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $94.48, for a total transaction of $188,771.04. Following the completion of the transaction, the senior vice president now directly owns 27,246 shares of the company’s stock, valued at approximately $2,574,202.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alan H. Auerbach sold 13,175 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the transaction, the insider now directly owns 4,170,623 shares of the company’s stock, valued at $395,083,116.79. The disclosure for this sale can be found here. Insiders have sold a total of 45,173 shares of company stock worth $4,738,189 over the last 90 days. Corporate insiders own 22.70% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.